Please login to the form below

Not currently logged in
Email:
Password:

liver cancer

This page shows the latest liver cancer news and features for those working in and with pharma, biotech and healthcare.

BMS scores FDA priority review for Opdivo/Yervoy combo in liver cancer

BMS scores FDA priority review for Opdivo/Yervoy combo in liver cancer

Hepatocellular carcinoma is the most common type of primary liver cancer, and it is often diagnosed in the advanced stages with a poor prognosis. ... The FDA’s acceptance of our application for Opdivo plus Yervoy represents important progress for

Latest news

  • Roche eyes filings for Tecentriq/Avastin combo in liver cancer Roche eyes filings for Tecentriq/Avastin combo in liver cancer

    Another important milestone for Roche's Tecentriq plans. Roche has phase 3 data with a combination of its checkpoint inhibitor Tecentriq with older cancer drug Avastin in liver cancer that it ... Roche is also stressing the importance of a filing in China

  • Arbutus hit hard as new hep B drug fails on safety Arbutus hit hard as new hep B drug fails on safety

    in time – a fairly sizeable minority develops chronic HBV that resists drug treatment and can lead to cirrhosis and liver cancer.

  • GSK to develop Ionis hepatitis B drugs GSK to develop Ionis hepatitis B drugs

    While hepatitis C now has an effective set of treatments which can cure virtually all patients, hepatitis B remains difficult to treat, and can lead to cirrhosis, liver failure and liver ... cancer. Current treatments for patients with CHB provide low

  • Positive first-line phase 3 results for Tecentriq Positive first-line phase 3 results for Tecentriq

    If Tecentriq can meet the secondary endpoints of the study as a first-line treatment, the drug could see Roche establish dominance in the bladder cancer market. ... results from the use of Tecentriq in a wider population of people with bladder cancer,

  • Transgene slumps as viral cancer therapy fails phase 3 trial Transgene slumps as viral cancer therapy fails phase 3 trial

    French biotech Transgene has abandoned a phase 3 trial of its SillaJen-partnered liver cancer therapy after an interim analysis suggested almost no chance of a positive outcome. ... PHOCUS was testing whether a dose of Pexa-Vec given ahead of Nexavar

More from news
Approximately 12 fully matching, plus 118 partially matching documents found.

Latest Intelligence

  • Making Europe a leader in bioscience: boosting trust and opening minds Making Europe a leader in bioscience: boosting trust and opening minds

    This public-private research alliance is aimed at improving survival rates in hepatocellular carcinoma (the primary cancer of the liver). ... of this cancer.

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    13 new targeted medicines that block the growth and spread of cancer by interfering with specific molecular targets. ... Other oncolytic viruses are coming through the pipeline, including SillaJen/Transgene’s Pexa-Vec for liver cancer and other solid

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    Co-development was another area in which major pharma firms were active, particularly Lilly, which enlarged its work with Boehringer Ingelheim to add in breast cancer programmes and closed a ... NASH and biosimilars. One therapeutic indication that could

  • Pharma deals in April 2015 Pharma deals in April 2015

    The treatment combines an antibody engineered to target CD19 with the cancer-killing agent maytansinoid. ... Menarini AP will be responsible for the clinical development, regulatory approval and commercialisation of resminostat in all oncological

  • Pharma deals during September 2013 Pharma deals during September 2013

    The lead pipeline candidates are SGI-110, a subcutaneous hypomethylating agent in multiple studies for a variety of haematological and solid tumour oncology indications, including MDS, AML, ovarian cancer and liver ... cancer, and AT13387, a second

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Using human insights to push healthcare communications forward
This blog highlights the value of human perspectives, showing how insights can propel healthcare communications forward to ultimately improve lives...
RWE Blog 4: The place of real-world evidence in the market access strategy
The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in...
RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...

Infographics